Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...

Celltrion, a major South Korean biopharmaceutical firm, on Tuesday said it aims to achieve 5 trillion won ($3.46 billion) in s ...

Korean pharmaceutical giant Celltrion on Tuesday pledged to achieve an annual growth rate of 30 percent and a return on equity of at least 7 percent by 2027, as part of its long-term initiative aimed ...

Trade volume was moderate at 359.99 million shares worth 6.84 trillion won ($4.7 billion) with decliners outpacing gainers ...

Nextrade boosts stock offerings to include Samsung, SK Hynix Investors can trade large-cap stocks on Koreas first alternative ...

Celltrion announced the commercial launch of STEQEYMA® (ustekinumab-stba), a biosimilar of Janssen’s STELARA® (ustekinumab), in the United States. As we previously reported, the biosimilar was ...

KOSPI briefly rises after Prime Ministers impeachment dismissal, then declines KOSPI dips after initial rise following Prime ...

Osteoporosis drug Prolia faces intense competition as patents expire and generics launch Intense rivalry emerges in the ...

Teva and Celltrion’s attempt to muscle in on the multi-billion dollar US cancer and inflammatory disease drug market has hit a setback after the FDA rejected two key biosimilars because of ...